IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2024.103871

Keiko Miyazato , Hiroshi Ohtsu , Akihiko Shimomura , Naohiro Yonemoto , Chikako Shimizu , Kazuhiro Sase , Shinichiro Ueda

{"title":"Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Receipt Claim Database","authors":"Keiko Miyazato , Hiroshi Ohtsu , Akihiko Shimomura , Naohiro Yonemoto , Chikako Shimizu , Kazuhiro Sase , Shinichiro Ueda","doi":"10.1016/j.breast.2024.103871","DOIUrl":"10.1016/j.breast.2024.103871","url":null,"abstract":"<div><div>Standard trastuzumab therapy can reduce the risk of early recurrence of HER2-positive breast cancer. However, trastuzumab-induced cardiac dysfunction may force the discontinuation of adjuvant trastuzumab therapy. Incidentally, there are still unclear whether or not trastuzumab treatment should be continued in the setting of reduced cardiac function. We aimed to investigate the association between trastuzumab discontinuation, the development of cardiac dysfunction during trastuzumab treatment, and all-cause mortality using the JMDC as the Japanese claims database. Between 2010 and 2019, 1779 women with early-stage breast cancer underwent surgery with adjuvant trastuzumab therapy (TZ). A 1:1 propensity score (PS) matching was conducted for patients who completed or discontinued TZ. The rates of cancer therapy-related-cardiovascular toxicity (CTR-CVT) and mortality in the TZ completion and discontinuation groups were compared. After PS matching, the TZ completion group (CMP_PSM: n = 83) and discontinuation group (INT_PSM: n = 83) were included in the study. TZ was administered for 12 and 5 months in CMP_PSM and INT_PSM, respectively. The cumulative incidence of CTR-CVT was significantly higher in CMP_PSM than INT_PSM (log-rank test, <em>P</em> = .0096). The mortality rate was significantly higher in INT_PSM than in CMP_PSM. The all-cause mortality in INT_PSM tended to increase at a constant rate after treatment, even after discontinuation. Our findings suggest that discontinuation of trastuzumab treatment worsens patient prognosis due to insufficient treatment of breast cancer rather than due to the cardiovascular toxicity of the drug.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103871"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

P053: Genomic profiling of metastatic phyllodes tumors identify potential therapeutic strategies

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103936

Y. Yang, W.-H. Kuo, H.-C. Lien, C.-S. Huang, Y.-S Li

引用次数: 0

P061: Tumor-infiltrating lymphocytes and tertiary lymphoid structures are associated with a higher upstaging risk of ductal carcinoma in situ in breast biopsies

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103938

C.-Y. Huang, Y.-J. Wang, Y.-H. Lee

引用次数: 0

P068: Systematic review of concordance between core biopsy and surgical excision for tumour biomarkers in neoadjuvant breast cancer patients

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103942

H.T.C. Chau, X. Lin, A. Shanmugalingam, N Ngui

引用次数: 0

P095: Breast Cancer Decision Support: Expert Systems vs. Machine Learning

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103962

M. Khanbhai, V. Patkar, D. Ruta, A. Kothari, H. Kristeleit, M Kazmi

引用次数: 0

P097: The Role of Breast Nurse in Ultrasound Guided Breast Core Biopsy

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103964

A. Plausteiner, A Šelih

引用次数: 0

P013: Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103905

K. Wimmer, D. Hlauschek, M. Balic, G. Pfeiler, R. Greil, C.F Singer, S. Halper, G. Steger, C. Suppan, S.P. Gampenrieder, R. Helfgott, D. Egle, M. Filipits, R. Jakesz, L. Sölkner, C. Fesl, M. Gnant, F. Fitzal

引用次数: 0

P014: Indirect comparison suggests ribociclib combined with nonsteroidal aromatase inhibitors is significantly more effective than tamoxifen in premenopausal women with Early Breast cancer

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103906

D. Lüftner, M. Banys-Paluchowski, A.D. Hartkopf, M. Hörner, W. Janni, D. Langanke, V. Müller, A. Schneeweiss, M. Schmidt, M. Thill, M. Untch, A. Wöckel, L. Höllrich, J. Kreuzeder, A. Marx, J. Meinzinger, H. Regus-Leidig, C. Roos, H. Wohlgemuth, S. Sussmann, P.A Fasching

引用次数: 0

P005: Impact of Dose Reductions on Efficacy of Adjuvant Abemaciclib for Patients with High Risk Early Breast Cancer: Analyses from the monarchE Study

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103899

V. Andre, J. O'Shaughnessy, I. Cicin, L. Testa, S. Tolaney, J. Huober, V. Guarneri, S. Johnston, M. Martin, P. Rastogi, N. Harbeck, H. Rugo, R. Wei, A. Shahir, M Goetz

引用次数: 0

P050: Genomic risk assessment with Oncotype DX in youngwomen (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer

IF 5.7 2区医学

Breast Pub Date : 2025-02-01 DOI: 10.1016/j.breast.2025.103933

R. Iosifidou, G. Xepapadakis, V. Venizelos, C. Markopoulos, K. Papazisis, N. Tsoulos, G. Kapetsis, S. Giannoulakis, M. Paraskeva, M. Kaparelou, G. Lainakis, A. Fotarelli, F. Pavlidou, E. Fountzilas, E. Saloustros, S. Karageorgopoulou, S. Triantafillidou, S. Intzes, F Koinis

引用次数: 0

Breast最新文献